CareDx Partners with European Society for Organ Transplantation to Support Assessment

 CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its membership on the clinical evidence supporting the use of donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ health.

“CareDx’s partnership with the European Society for Organ Transplantation represents a key step forward in educating the European transplant community about the clinical utility of AlloSeq cfDNA, our kit version to allow donor-derived cell-free DNA assessment,” said Reg Seeto, CEO and President of CareDx. “AlloSeq provides clinical information about allograft injury and the risk of rejection. We look forward to working with ESOT in expanding access to this leading technology, and over time making it the standard of care for organ transplant patients globally.”

https://finance.yahoo.com/news/caredx-partners-european-society-organ-110000005.html